FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation